INFLUENCE OF SYSTEMIC CONDITIONS ON PERIODONTAL DISEASE AND VICE VERSA

INTRODUCTION

DEFINITION AND PATHOGENESIS: THE FOUNDATION FOR SYSTEMIC LINKS

• Bacterial challenge: dysbiotic biofilm triggers pattern recognition receptor (PRR) activation including Toll-like receptors (TLRs)
• Innate and adaptive immune dysregulation: excessive release of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α, IL-17)
• Matrix metalloproteinase (MMP) activation: leading to connective tissue and bone destruction
• Impaired resolution of inflammation: failure of lipoxin/resolvin-mediated resolution pathways

PART I: INFLUENCE OF SYSTEMIC CONDITIONS ON PERIODONTAL DISEASE

1. Diabetes Mellitus

DM as a Risk Factor for Periodontitis

• Individuals with DM face a 2- to 4-fold elevated risk of developing periodontitis compared to normoglycemic individuals (Wu et al., 2026).
• Type 2 DM shows a particularly strong correlation with periodontitis, especially in middle-aged populations.
• Type 1 DM predisposes children and adolescents to accelerated periodontal destruction, with disease duration and suboptimal glycemic control further amplifying risk.
• Women with gestational DM (GDM) also exhibit heightened susceptibility, as confirmed by a 2025 systematic review and meta-analysis (García-Martos et al., Prim Care Diabetes, 2025, PMID: 39627087).
• Glycated hemoglobin (HbA1c) levels are now recommended for stratifying periodontitis severity.

Mechanisms by which Hyperglycemia Worsens Periodontal Disease

1. Advanced Glycation End-products (AGEs) / RAGE axis: Hyperglycemia leads to irreversible formation of AGEs and upregulation of their receptors (RAGE). AGE-RAGE interactions amplify oxidative stress and NF-κB mediated inflammation, increasing IL-1β, TNF-α, and IL-6 production. This causes exaggerated tissue destruction and impairs repair.
2. RANKL/OPG axis dysregulation: DM directly and indirectly (via AGE/RAGE) modulates the RANKL/OPG ratio, promoting osteoclastogenesis and alveolar bone loss.
3. Immune cell dysfunction: Hyperglycemia impairs neutrophil chemotaxis, phagocytosis, and intracellular killing, rendering the periodontal tissues more susceptible to microbial invasion.
4. Subgingival dysbiosis: Glucose-rich gingival crevicular fluid (GCF) in diabetics alters the subgingival microbiome, favoring the proliferation of periodontal pathogens.
5. Cytokine imbalance: Elevated circulating adipokines (leptin, resistin, adiponectin dysregulation) in diabetics with adiposity contribute to a pro-inflammatory state that worsens periodontal breakdown.
6. Impaired wound healing: Reduced fibroblast function, impaired angiogenesis, and diminished growth factor production compromise periodontal tissue repair.

2. Cardiovascular Disease (CVD)

• Patients with established CVD, particularly those with coronary artery disease, have been shown to have higher prevalence and severity of periodontitis.
• The pro-inflammatory and pro-thrombotic systemic state in CVD creates a milieu that amplifies local periodontal inflammation.
• Common risk factors including smoking, oxidative stress, and endothelial dysfunction are shared by both conditions.

3. Rheumatoid Arthritis (RA)

• The systemic pro-inflammatory state of RA (elevated TNF-α, IL-1β, IL-6, IL-17) lowers the threshold for periodontal tissue destruction.
• Both RA and periodontitis feature:
  • Osteoclast-mediated bone destruction (RANKL/OPG axis)
  • B-cell and plasma cell dysregulation
  • Th17 cell-mediated inflammation
  • Autoantibody production (anti-citrullinated protein antibodies, or ACPAs)
• Shared genetic predisposition: HLA-DRB1-04 allele is associated with susceptibility to both conditions (Wu et al., 2026).
• Shared environmental risk factors: Smoking is a potent risk factor for both diseases.
• Common infectious triggers: Epstein-Barr virus and cytomegalovirus infections have been implicated in both RA and periodontitis.

4. Obesity and Metabolic Syndrome

• Adipose tissue acts as an endocrine organ secreting pro-inflammatory adipokines (leptin, resistin, chemerin) that promote systemic and periodontal inflammation.
• A cross-sectional study found that serum chemerin levels - an adipokine linked to inflammatory regulation - were statistically significantly higher in patients with chronic periodontitis than in periodontally healthy individuals across all BMI categories (Villoria et al., 2024).
• Furthermore, both IL-1β, IL-6, and TNF-α were notably higher in the serum of patients with chronic periodontitis across body mass categories.
• Metabolic syndrome components (central obesity, hypertriglyceridemia, reduced HDL, hypertension, insulin resistance) collectively amplify periodontal susceptibility through insulin resistance, oxidative stress, and inflammatory mechanisms.
• A 2024 meta-analysis (Lu et al., Clin Oral Investig, PMID: 38801482) confirmed that periodontitis plays a role in atherosclerotic CVD development in individuals with metabolic syndrome.

5. Respiratory Diseases

• In COPD, the systemic inflammatory load (elevated CRP, IL-6, fibrinogen) and shared risk factors (smoking) promote periodontal inflammation.
• The pulmonary microenvironment in respiratory disease may influence oral microbial ecology through altered mucosal immunity.
• Steroid use in asthma management suppresses immune responses, potentially modifying the periodontal host response.
• Obstructive sleep apnea (OSA): A meta-analysis (Zhang et al., 2022) confirmed that OSA is associated with increased risk of periodontitis, likely through intermittent hypoxia-driven oxidative stress and systemic inflammation.

6. Chronic Kidney Disease (CKD)

• Patients with CKD face a 2-fold elevated risk of periodontitis compared to individuals with normal renal function (NHANES III data, cited in Wu et al., 2026).
• The uremic state in CKD impairs neutrophil function, alters salivary composition (increased urea, altered pH), and creates immunosuppression that worsens periodontal susceptibility.
• Uremic stomatitis, xerostomia, and altered GCF composition further compromise periodontal defenses.

7. Hormonal Changes: Puberty, Pregnancy, and Menopause

• Gingival tissues contain receptors for estrogen and progesterone.
• Elevated progesterone during pregnancy: increases gingival vascular permeability, inhibits phagocytosis, promotes prostaglandin E2 (PGE2) production.
• Pregnancy gingivitis: occurs in up to 75% of pregnant women due to elevated progesterone levels, even with low plaque scores.
• Puberty gingivitis: androgens and estrogens in puberty increase Prevotella intermedia colonization (which substitutes sex hormones for naphthoquinone as a growth factor).
• Menopause: Estrogen deficiency leads to osteoporosis, which can accelerate alveolar bone loss in conjunction with periodontal disease.
• Oral contraceptive use: combined estrogen-progesterone pills have been associated with gingival inflammation.

8. HIV/AIDS and Immunosuppression

• HIV infection causes CD4+ T-lymphocyte depletion, profoundly impairing periodontal host defenses.
• HIV-associated periodontal diseases include: linear gingival erythema (LGE), necrotizing ulcerative gingivitis (NUG), and necrotizing ulcerative periodontitis (NUP) - conditions rarely seen in immunocompetent patients.
• NUP in HIV/AIDS patients presents with rapid bone destruction, severe pain, necrosis, and is an AIDS-defining condition.
• CD4 counts below 200 cells/mm³ are associated with the most severe periodontal manifestations.
• Immunosuppressive medications (used in organ transplant recipients, cancer patients) similarly compromise periodontal immunity, and some (cyclosporine, calcium channel blockers, phenytoin) cause drug-induced gingival overgrowth.

9. Osteoporosis

• Systemic osteoporosis shares the common mechanism of increased osteoclastic activity (RANKL upregulation, reduced OPG) with alveolar bone loss in periodontitis.
• Studies have shown that postmenopausal women with osteoporosis have greater clinical attachment loss, higher tooth loss rates, and more radiographic alveolar bone loss.
• Bisphosphonate therapy used for osteoporosis, while protecting systemic bone, poses the risk of medication-related osteonecrosis of the jaw (MRONJ) following periodontal procedures.

PART II: INFLUENCE OF PERIODONTAL DISEASE ON SYSTEMIC CONDITIONS

1. Bacteremia: transient or episodic entry of oral bacteria into the bloodstream through the ulcerated pocket epithelium
2. Endotoxemia: systemic dissemination of bacterial products (LPS, gingipains, fimbriae) from periodontal pathogens
3. Systemic cytokine spillover: local pro-inflammatory mediators (IL-1β, IL-6, TNF-α, PGE2) entering systemic circulation and amplifying systemic inflammation

1. Periodontal Disease and Cardiovascular Disease

Epidemiological Evidence

• An umbrella review (Arbildo-Vega et al., BMC Oral Health, 2024, PMID: 39468505) comprehensively confirmed the association between periodontal and cardiovascular diseases.
• A 2024 systematic review (Kim et al., Mol Cells, PMID: 39515611) on Periodontitis and atherosclerotic cardiovascular disease established robust evidence for a causal pathway.
• A 2026 systematic review and meta-analysis (Li et al., BMC Oral Health, PMID: 41618248) confirmed the association between periodontitis and acute myocardial infarction.
• A systematic review on dental and cardiovascular diseases (Hardan et al., Rev Cardiovasc Med, 2023, PMID: 39077523) further substantiated these links.

Mechanisms Linking Periodontitis to CVD

• Periodontal pathogens exploit the compromised gingival epithelial barrier to access systemic circulation.
• P. gingivalis and Streptococcus mutans have been detected in atherosclerotic plaques by polymerase chain reaction studies (Isola et al., 2023).
• Virulence factors including lipopolysaccharide (LPS) and gingipains of P. gingivalis:
  • Disrupt complement components and their receptors
  • Impair neutrophil bactericidal activity
  • Facilitate macrophage uptake of oxidized LDL (ox-LDL), promoting foam cell formation and expansion of the atherosclerotic plaque lipid core
  • Trigger molecular mimicry - autoimmune responses targeting vascular endothelium

• Chronic periodontal lesions release pro-inflammatory mediators that:
  • Directly damage endothelial cells
  • Inhibit endothelial nitric oxide synthase (eNOS) activity, reducing NO production
  • Elevate reactive oxygen species (ROS) and adhesion molecules (VCAM-1, ICAM-1)
  • Promote monocyte adhesion and foam cell formation, accelerating atherosclerosis progression
  • Stimulate fibroblast proliferation, cardiac remodeling, and arterial stiffening

• Elevated fibrinogen levels (a major predictor of atherosclerosis) have been found in periodontitis patients. Fibrinogen and its degradation products stimulate inflammatory mediators and reduce plasminogen activator inhibitor synthesis, increasing thrombosis risk (Isola et al., 2023).
• Platelet activation by periodontal pathogens contributes to the pro-thrombotic state.

• CRP (C-reactive protein): A meta-analysis by Machado et al. (Front Immunol, 2021, PMID: 34394107) confirmed elevated serum CRP levels in periodontitis patients. CRP is synthesized by the liver in response to IL-6 and is a primary biomarker for cardiovascular risk.
• Circulating inflammatory cells in periodontitis: A systematic review by Irwandi et al. (J Leukoc Biol, 2022, PMID: 35199874) confirmed altered inflammatory cell profiles.
• Non-surgical periodontal therapy (NSPT) in patients with stable coronary artery disease decreased serum TNF-α, IL-6, and CRP levels, potentially reducing the cardiovascular inflammatory burden (Villoria et al., 2024).

Specific CVD Outcomes

• Atherosclerosis: Periodontitis accelerates atheromatous plaque formation and progression.
• Myocardial Infarction: Multiple studies confirm increased MI risk in patients with severe periodontitis.
• Stroke: Periodontitis is associated with increased ischemic stroke risk.
• Heart failure: Left ventricular hypertrophy and cardiac remodeling through systemic inflammatory and oxidative stress pathways.
• Atrial fibrillation: Association demonstrated through inflammatory and autonomic mechanisms.
• Peripheral artery disease: Inflammatory vascular damage extends beyond coronary and cerebral vessels.

2. Periodontal Disease and Diabetes Mellitus

Periodontal Disease Worsening Glycemic Control

1. Systemic dissemination of periodontal pathogens and their products impair insulin signaling and increase insulin resistance - leading to elevated HbA1c levels and worsening diabetic complications.
2. Hepatic metabolic disruption: LPS and bacterial products inhibit hepatic glycogen synthesis and enhance hepatic gluconeogenesis.
3. Inflammatory cytokine-mediated insulin resistance: TNF-α and IL-6 from periodontal tissues directly interfere with insulin receptor signaling (IRS-1 phosphorylation), impair GLUT4 translocation, and promote insulin resistance.
4. AGE production: Periodontal infection amplifies AGE formation in diabetics, creating a positive feedback loop that worsens both glycemia and periodontal destruction.

Clinical Evidence: Periodontal Treatment Improving Glycemic Control

3. Periodontal Disease and Adverse Pregnancy Outcomes

Pregnancy Outcomes Associated with Periodontitis

• Preterm birth (PTB): Maternal periodontitis increases risk by 2- to 6-fold (Wu et al., 2026). Periodontal bacteria (particularly Fusobacterium nucleatum and P. gingivalis) have been detected in amniotic fluid, placental membranes, and umbilical cord blood of women with PTB.
• Low birth weight (LBW): Strong association in multiple studies.
• Preeclampsia: Periodontal inflammation-driven endothelial dysfunction and elevated systemic inflammatory mediators may contribute.
• Miscarriage: Bacteremia and cytokine-mediated mechanisms implicated.

Mechanisms

1. Bacterial translocation: Oral pathogens cross the placental barrier and colonize chorioamniotic membranes, causing chorioamnionitis.
2. Prostaglandin E2 (PGE2): Systemically elevated PGE2 from periodontal tissues can stimulate uterine contractions and cervical ripening, triggering preterm labor.
3. Inflammatory mediators: Elevated IL-6 and TNF-α from periodontal disease activate the prostaglandin cascade and matrix metalloproteinases in amniotic membranes.
4. Endotoxin (LPS): Systemic LPS stimulates cytokine production that drives parturition pathways.

4. Periodontal Disease and Respiratory Disease

• Aspiration of oral pathogens into the lower respiratory tract causes aspiration pneumonia, particularly in elderly and institutionalized patients.
• P. gingivalis, Fusobacterium nucleatum, Prevotella intermedia, and anaerobic species from periodontal pockets are implicated.
• Studies in ICU patients show that improved oral hygiene reduces ventilator-associated pneumonia (VAP) incidence.

• A bidirectional relationship exists: COPD increases periodontal susceptibility (through systemic inflammation, steroid use, xerostomia from breathing patterns), while periodontitis exacerbates COPD through systemic inflammatory load.
• Both conditions share smoking as a major risk factor and overlapping inflammatory pathways.

• Chronic periodontitis increases lung cancer risk by approximately 2.3-fold, more pronounced in middle-aged non-smoking women (Wu et al., 2026).
• The microbial and inflammatory milieu of periodontal disease contributes to carcinogenesis through genotoxic bacterial products (nitrosamines), chronic mucosal inflammation, and immunosuppression.
• A meta-analysis confirmed this association (Wu et al., 2026, citing refs 93, 94).

• Moderate evidence of association; some Mendelian randomization studies suggest immune suppression pathways may explain the relationship (Wu et al., 2026).

5. Periodontal Disease and Alzheimer's Disease/Cognitive Decline

Epidemiological Evidence

• Periodontitis increases the risk of Alzheimer's disease by 1.7-fold (Wu et al., 2026).
• A systematic review by Borsa et al. (Int J Environ Res Public Health, 2021, PMID: 34501899) confirmed the link between periodontal diseases and AD.

Mechanisms

1. Blood-Brain Barrier (BBB) penetration: P. gingivalis gingipains (toxic protease virulence factors) have been detected in the brains of Alzheimer's patients. These enzymes cleave complement and host defense proteins, facilitating BBB penetration.
2. Amyloid-beta (Aβ) and Tau pathology: P. gingivalis infection triggers neuroinflammation leading to accelerated Aβ and Tau pathology in animal models. Targeted COR388 (atuzaginstat) therapy against P. gingivalis gingipains showed slowing of AD progression in clinical trials (Wu et al., 2026).
3. Neuroinflammatory cytokine cascade: Peripheral pro-inflammatory mediators (TNF-α, IL-1β, CRP) produced in periodontal disease cross the BBB via systemic circulation, activating microglia and establishing a neuroinflammatory cycle.
4. Enhanced BBB permeability: The low-grade systemic inflammatory milieu associated with aging and periodontitis enhances BBB permeability, facilitating pathogen and cytokine entry into the CNS.
5. Cholinergic dysfunction and synaptic loss: Periodontal bacteria trigger excessive cytokine secretion, promoting neurodegeneration and death of neurons.

6. Periodontal Disease and Chronic Kidney Disease

• CKD patients face a 2-fold elevated risk of periodontitis (NHANES III data).
• Moderate-to-severe periodontitis correlates with CKD-related mortality.
• Periodontal therapy (PT) may improve CKD status by mitigating systemic inflammatory burden, as confirmed by a systematic review (Wu et al., 2026).

• P. gingivalis fimbrial proteins, LPS, and gingipains trigger inflammatory responses causing renal damage via NF-κB activation.
• A. actinomycetemcomitans induces destructive immune responses through PGN, outer membrane vesicles (OMVs), cytolethal distending toxin (CDT), and leukotoxin (LtxA), activating PI3K signaling.
• F. nucleatum FadA adhesin activates NF-κB and p38 MAPK signaling, contributing to renal injury.
• IL-1 and IL-6 from periodontitis induce Th17 cell differentiation, with IL-17A stimulating renal tubular epithelial cells and promoting tubulointerstitial fibrosis.
• Systematic review and meta-analysis by Ferreira et al. (Oral Diseases, 2024, PMID: 38720642) confirmed these associations.

7. Periodontal Disease and Rheumatoid Arthritis

Molecular Mimicry: The Citrullination Hypothesis

• P. gingivalis is unique among oral pathogens in producing a bacterial peptidylarginine deiminase (PPAD) enzyme that citrullinates host and bacterial proteins.
• Citrullination generates neo-antigens recognized by the immune system, triggering the production of anti-citrullinated protein antibodies (ACPAs) - the hallmark autoantibody of RA.
• This mechanism provides a biological explanation for why periodontitis may be an etiological trigger for RA.

Bidirectional Clinical Evidence

• Non-surgical periodontal therapy (NSPT) in RA patients resulted in significantly decreased disease activity scores (DAS28) and CRP levels, suggesting NSPT may serve as an adjunctive treatment for RA (Wu et al., 2026; Joseph et al., Clin Oral Investig, 2023, PMID: 38147183).
• A correlation analysis confirmed by Rak et al. (2024, PMID: 38869834).

8. Periodontal Disease and Cancer

Oral Cancer

• Chronic inflammation from periodontitis creates a mucosal microenvironment conducive to oral squamous cell carcinoma (OSCC). Malignant cells exposed to inflammatory signals develop chemoresistance and more aggressive biological behavior, promoting tumor progression (Isola et al., 2023).

Colorectal Cancer (CRC)

• Fusobacterium nucleatum, a periodontal pathogen, has been identified in colorectal cancer tissues. DNA sequencing studies confirm its presence in CRC tumors (Isola et al., 2023).
• F. nucleatum promotes oncogenesis through FadA adhesin, activating Wnt/β-catenin signaling and driving epithelial-to-mesenchymal transition.

Pancreatic Cancer

• Patients with periodontal disease have increased pancreatic cancer mortality (Isola et al., 2023).

Breast Cancer

• Two longitudinal studies (1,676 and 7,373 women respectively, with follow-up periods of 18 and 6.7 years) reported an enhanced risk of breast cancer in patients with periodontitis.
• Two meta-analyses concluded that periodontitis may increase breast cancer risk, with periodontal therapy recommended in its prevention (Isola et al., 2023).

Esophageal and Gastric Cancer

• P. gingivalis has been detected in esophageal carcinoma tissues, with higher bacterial loads correlating with higher tumor grades.
• Periodontitis increases the risk of esophageal squamous cell carcinoma.

9. Periodontal Disease and Helicobacter pylori Infection

• The subgingival plaque serves as a reservoir for H. pylori, explaining why gastric eradication may fail without oral decontamination.
• H. pylori eradication reduces periodontitis risk, and NSPT reduces both periodontal and gastric H. pylori burden.
• However, findings regarding subgingival vs. gastric tissue findings remain controversial due to methodological limitations.

PART III: SHARED PATHOPHYSIOLOGICAL MECHANISMS - THE UNIFYING FRAMEWORK

1. Bacterial Translocation

• Oral pathogens exploit the ulcerated pocket epithelium (total PISA of up to 72 cm² in severe disease) to gain access to systemic circulation.
• Bacteremic episodes of up to 100-500 CFU/mL occur during mastication, toothbrushing, and dental procedures in patients with periodontitis.
• Translocated pathogens engage PRRs (TLRs) on dendritic cells and macrophages, triggering cytokine storms (IL-1β, TNF-α, IFN-γ).
• DNA sequencing has confirmed oral bacterial DNA in atheromas, amniotic fluid, colorectal cancer tissue, and the brains of AD patients (Isola et al., 2023).

2. Systemic Inflammation

• The periodontal inflammatory lesion generates a constant outpouring of IL-1β, IL-6, TNF-α, PGE2, and matrix metalloproteinases into systemic circulation.
• This produces a low-grade chronic systemic inflammatory state.
• Elevated serum CRP is consistently documented in periodontitis and serves as a bridge mediator for CVD risk.
• NSPT reduces serum IL-6, IL-8, TNF-α, and CRP levels, confirming that periodontal disease actively drives systemic inflammation.
• A systematic review (Machado et al., 2021, PMID: 34394107) demonstrated elevated CRP in periodontitis; and a meta-analysis (Irwandi et al., 2022, PMID: 35199874) confirmed circulating inflammatory cell profile alterations.

3. Immune Dysregulation

• Periodontitis dysregulates both innate and adaptive immunity:
  • Maladaptive innate immune training (trained immunity): Repeated exposure to periodontal bacterial PAMPs epigenetically reprograms myeloid cells toward a hyper-inflammatory phenotype that persists in systemic circulation (Li et al., Cell, 2022; cited in Villoria et al., 2024).
  • Autoantibody induction: ACPA production through citrullination.
  • Th17/Treg imbalance: Th17 cells promote systemic inflammation while Treg suppression leads to loss of tolerance.
  • Complement dysregulation: P. gingivalis specifically hijacks complement C5 signaling to evade clearance while amplifying local and systemic inflammation.

4. Oxidative Stress

• Periodontal inflammation generates excessive reactive oxygen species (ROS) from activated neutrophils and macrophages.
• Systemic oxidative stress damages endothelial cells (promoting atherosclerosis), increases lipid peroxidation, impairs insulin signaling (contributing to diabetes), and causes DNA damage (contributing to carcinogenesis).
• ROS-mediated inhibition of eNOS reduces vascular NO production, impairing endothelial function and promoting hypertension and atherosclerosis.

PART IV: THE CONCEPT OF PERIODONTITIS AS A SYSTEMIC DISEASE

1. The medical definition of a systemic disease includes diseases that affect different organs and systems - which periodontitis clearly does.
2. Periodontitis produces a pro-inflammatory state analogous to other recognized systemic NCDs (like RA, IBD, COPD) and a pro-thrombotic state with elevated immunological activity.
3. The multimorbidity burden: A large-scale study found that individuals with periodontal disease are significantly more likely to be burdened by comorbidities than those without (46.3% vs. 30.9%; adjOR 1.36, CI 1.30-1.43). Periodontal disease can be considered part of multimorbidity clusters (Villoria et al., 2024).
4. Shared genetic susceptibility: Common genetic factors contribute to both periodontal and systemic diseases (Aarabi et al., J Dent Res, 2017; Harroud & Hafler, Science, 2023).
5. The dysbiosis-barrier dysfunction-immune activation interplay creates a self-perpetuating positive feedback loop maintaining both periodontal tissues and systemic circulation in a state of chronic inflammation (Wu et al., 2026).

PART V: CLINICAL IMPLICATIONS AND MANAGEMENT

Interdisciplinary Care Model

1. Medical history taking in periodontal patients: Screen for DM (HbA1c), CVD, RA, CKD, respiratory disease, pregnancy status, and medication history.
2. Periodontal screening in systemic disease patients: Every diabetic, cardiac, RA, CKD, and pregnant patient should receive periodontal evaluation.
3. NSPT as adjunctive systemic therapy: Evidence supports that NSPT:
   • Reduces HbA1c in T2DM (Cochrane review, Simpson et al., 2022)
   • Reduces serum CRP, IL-6, and TNF-α in CVD patients
   • Reduces DAS28 and CRP in RA patients
   • May improve CKD-related inflammatory parameters
4. Adjunctive local therapies: A network meta-analysis (Lin et al., J Dent, 2024, PMID: 38936456) evaluated adjunctive local periodontal treatments for T2DM patients.
5. Common risk factor approach (Genco & Genco, 2014): Addressing shared modifiable risk factors - smoking cessation, dietary modification, weight management, glycemic control - benefits both periodontal and systemic health simultaneously.
6. Systemic NSPT efficacy: A systematic review and meta-analysis (Joseph et al., Clin Oral Investig, 2023, PMID: 38147183) evaluated NSPT efficacy across multiple concurrent systemic conditions.

EFP/WONCA Consensus

• Management of periodontitis in patients with CVD, diabetes, and respiratory diseases
• Communication protocols between dental and medical professionals
• Patient education on periodontal-systemic links

SUMMARY TABLE: PERIODONTAL DISEASE AND SYSTEMIC CONDITIONS

CONCLUSION

1. Systemic diseases influence periodontal disease - through immune impairment, altered host responses, vascular changes, hormonal effects, and shared microbial/inflammatory mechanisms.
2. Periodontal disease influences systemic health - through bacteremia, endotoxemia, systemic cytokine spillover, oxidative stress, and immune dysregulation affecting virtually every organ system.
3. The association is bidirectional and synergistic in most conditions studied - creating vicious cycles that amplify both disease processes simultaneously.
4. Periodontal treatment has documented systemic benefits - NSPT reduces HbA1c, CRP, DAS28, and inflammatory burden in patients with concurrent systemic diseases.
5. A paradigm shift is warranted: As Villoria et al. (2024) proposed, periodontitis should be considered a systemic disease in its own right, integrated into the broader framework of non-communicable disease management.

REFERENCES (KEY CITATIONS)

1. Isola G, Santonocito S, Lupi SM et al. (2023). Periodontal Health and Disease in the Context of Systemic Diseases. Mediators of Inflammation, 2023:9720947. https://doi.org/10.1155/2023/9720947
2. Villoria GEM, Fischer RG, Tinoco EMB, Meyle J, Loos BG. (2024). Periodontal disease: A systemic condition. Periodontology 2000, DOI: 10.1111/prd.12616.
3. Wu Z, Zhang Y, Wang L, Yi Y, Dai B, Chen H, Yang F. (2026). Periodontitis and systemic diseases: insights into the correlation, mechanisms, and clinical implications. Front Immunol, 17:1777955. DOI: 10.3389/fimmu.2026.1777955
4. Herrera D, Sanz M, Shapira L et al. (2023). Association between periodontal diseases and cardiovascular diseases, diabetes and respiratory diseases: Consensus report of the Joint Workshop by EFP and WONCA Europe. J Clin Periodontol, 50(6):819-841. [PMID: 36935200]
5. Simpson TC, Clarkson JE, Worthington HV et al. (2022). Treatment of periodontitis for glycaemic control in people with diabetes mellitus. Cochrane Database Syst Rev, 2022(4). [PMID: 35420698]
6. Stöhr J, Barbaresko J, Neuenschwander M et al. (2021). Bidirectional association between periodontal disease and diabetes mellitus: a systematic review and meta-analysis of cohort studies. Sci Rep, 11:13686. [PMID: 34211029]
7. Kim JY, Lee K, Lee MG et al. (2024). Periodontitis and atherosclerotic cardiovascular disease. Mol Cells, 47(12). [PMID: 39515611]
8. Arbildo-Vega HI, Cruzado-Oliva FH, Coronel-Zubiate FT et al. (2024). Periodontal disease and cardiovascular disease: umbrella review. BMC Oral Health, 24:1257. [PMID: 39468505]
9. Li L, Wu H, Peng L et al. (2026). Association between periodontitis and acute myocardial infarction: a systematic review and meta-analysis. BMC Oral Health. [PMID: 41618248]
10. Rak D, Kulloli AM, Shetty SK et al. (2024). Correlation between rheumatoid arthritis and chronic periodontitis: a systematic review and meta-analysis. Minerva Dent Oral Sci. [PMID: 38869834]
11. Li Y, Guo R, Oduro PK et al. (2022). The Relationship Between Porphyromonas Gingivalis and Rheumatoid Arthritis: A Meta-Analysis. Front Cell Infect Microbiol, 12. [PMID: 35923803]
12. Ferreira SMSP, Gomes-Filho IS, Costa MDCN et al. (2024). Periodontitis and systemic parameters in chronic kidney disease: Systematic review and meta-analysis. Oral Dis. [PMID: 38720642]
13. Machado V, Botelho J, Escalda C et al. (2021). Serum C-Reactive Protein and Periodontitis: A Systematic Review and Meta-Analysis. Front Immunol, 12:706432. [PMID: 34394107]
14. Borsa L, Dubois M, Sacco G et al. (2021). Analysis the Link between Periodontal Diseases and Alzheimer's Disease: A Systematic Review. Int J Environ Res Public Health, 18(18):9575. [PMID: 34501899]
15. Joseph P, Prabhakar P, Holtfreter B et al. (2023). Systematic review and meta-analysis of RCTs evaluating the efficacy of non-surgical periodontal treatment in patients with concurrent systemic conditions. Clin Oral Investig. [PMID: 38147183]
16. Genco RJ, Genco FD. (2014). Common risk factors in the management of periodontal and associated systemic diseases. J Evid Based Dent Pract, 14(Suppl):4-16.
17. Löe H. (1993). Periodontal disease: the sixth complication of diabetes mellitus. Diabetes Care, 16(1):329-334.
18. Sanz M, Marco Del Castillo A, Jepsen S et al. (2020). Periodontitis and cardiovascular diseases: consensus report. J Clin Periodontol, 47(3):268-288.

What This Answer Covers (Exam Guide)

Structure at a Glance

Key Studies Cited

• Isola et al. 2023 (Mediators of Inflammation) - your first attachment
• Villoria et al. 2024 (Periodontology 2000) - your second attachment
• Wu et al. 2026 (Frontiers in Immunology) - your third attachment
• Simpson et al. 2022 (Cochrane review) - HbA1c reduction post-NSPT
• Herrera et al. 2023 (EFP/WONCA Consensus) - formal guideline on the association
• Stöhr et al. 2021 (Meta-analysis) - bidirectional DM-periodontitis link
• Li L et al. 2026 - periodontitis and acute MI
• Rak et al. 2024 - periodontitis and RA meta-analysis
• 18 total high-quality references with PMIDs